Kymera Therapeutics Profit Margin

Kymera Therapeutics (KYMR) currently reports a profit margin of -285.41% as of June 2026. That compares with -616.03% in the prior-year period — up 53.7% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Kymera Therapeutics's profit margin history and peer comparisons.

Kymera Therapeutics's profit margin increased from -616.03% to -285.41% — a 53.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kymera Therapeutics's profit margin of -285.41% is lower than the Healthcare sector average of 13.89%. That is roughly 2154.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Kymera Therapeutics's current -285.41% should be judged against Healthcare norms (sector average: 13.89%) and against KYMR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -285.41%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Kymera Therapeutics, and consider following KYMR for alerts when major investors trade the stock.